RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.
Also called NCT04485195
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 350 participants
- Registry
-
NCT04485195
-
- Other papers using this trial's data
- Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT04485195. Randomized; no masking; primary purpose treatment. Start 2021-06-17 (actual); primary completion 2024-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Vernakalant
- Intervention (Drug)
- Procainamide
- Lead sponsor
- Ottawa Hospital Research Institute
Record details
- Record id
cardio:ct-nct04485195- Content hash
63df26fb6c17f5e96b5b7acb4ded872277efe33bc84534bdaedeca51c57525cc